Greenwich Lifesciences Inc   (GLSI)
Other Ticker:  
Price: $12.9600 $-0.04 -0.308%
Day's High: $13.2 Week Perf: 3.68 %
Day's Low: $ 12.29 30 Day Perf: 45.78 %
Volume (M): 35 52 Wk High: $ 16.02
Volume (M$): $ 451 52 Wk Avg: $10.42
Open: $13.00 52 Wk Low: $7.58

 Market Capitalization (Millions $) 167
 Shares Outstanding (Millions) 13
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -8
 Cash Flow (TTM) (Millions $) -8
 Capital Exp. (TTM) (Millions $) 0

Greenwich Lifesciences Inc
Greenwich Lifesciences Inc is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapy drug candidates for the treatment of solid tumors. The company's lead product candidate, GP2, is a novel peptide immunotherapy intended to prevent breast cancer recurrence in patients who have previously undergone surgery. GP2 stimulates the immune system to recognize and destroy breast cancer cells expressing the HER2/neu protein, which is known to be present in certain breast cancer patients. Greenwich Lifesciences aims to provide an effective and safe treatment option for breast cancer patients at high risk of recurrence, ultimately improving their long-term outcomes.

   Company Address: 3992 Bluebonnet Dr. Stafford 77477 TX
   Company Phone Number: 819-3232   Stock Exchange / Ticker: NASDAQ GLSI
   GLSI is expected to report next financial results on March 30, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Astria Therapeutics Inc

2 CEO Jill C. Milne's Optimism and Commitment to Innovation Drive Astria Therapeutics Inc. Forward

The recent financial results of Astria Therapeutics Inc, a key player in the Major Pharmaceutical Preparations industry, have been a topic of interest among investors and industry experts alike. Despite reporting a net deficit and operating shortfall for the financial period ending December 31, 2023, the company remains optimistic about its future prospects. With a focus on developing groundbreaking therapies for allergic and immunological diseases, Astria Therapeutics has shown resilience and determination in a challenging market environment.
CEO Jill C. Milne's confidence in STAR-0215 as a potential game-changing preventative therapy for Hereditary Angioedema (HAE) is not to be underestimated. The company's commitment to innovation and patient care is evident in their financial performance and corporate updates, further solidifying their position as a leader in the biopharmaceutical industry.

Ani Pharmaceuticals Inc

2. Embracing Success: ANI Pharmaceuticals Inc's Remarkable Turnaround in Q4 2023

As a pharmaceutical industry enthusiast and an avid follower of ANI Pharmaceuticals Inc, I am thrilled to report on the recent financial results and business highlights of this major pharmaceutical preparations company. The October to December 31, 2023 fiscal time-frame has proven to be a turning point for ANI Pharmaceuticals Inc, as they have witnessed significant improvements in their earnings and revenue.
Starting with earnings per share, ANI Pharmaceuticals Inc saw a substantial positive shift from $-0.23 a year prior to $0.03 per share in the recent fiscal time-frame. This impressive improvement showcases the company's ability to effectively manage their financial performance and generate profits. Additionally, ANI Pharmaceuticals Inc reported earnings per share of $0.85 compared to $-3.05 in the previous fiscal year, indicating remarkable growth.

Chimerix Inc

Serious headline: Chimerix Inc Sees Decrease in Losses During Fourth Quarter of 2023

Chimerix Inc, a major pharmaceutical preparations company, experienced a decrease in their loss per share for the October to December 31, 2023 interval. The loss per share decreased from $-0.22 to $-0.20 compared to the same period the previous year. Additionally, their income per share improved from $-0.27 to -$0.20 from the prior quarter.
However, the company witnessed a sharp decline in revenue during this interval. The revenue dropped from $0.81 million in the same quarter the previous year to $0.00 million, and sequentially from $0.01 million.

Compass Pathways Plc

Compass Pathways Plc Reports Impressive Fourth Quarter Efforts Amidst Industry Growth

Compass Pathways Plc, a biotechnology company focused on mental health innovation, has experienced significant growth in its share price over the past year. According to recent financial results, the company's shares have risen by 24.72% compared to a year ago, reaching an impressive 69.55% increase in the past 90 days alone. This positive trend is further supported by the fact that Compass Pathways Plc shares are currently trading on the NASDAQ at a significant 22.4% above its 52-week average.
One factor that could potentially contribute to this growth is the company's collaboration with Hackensack Meridian Health (HMH) to optimize the clinical model for COMP360 psilocybin treatment, a psychedelic substance found in magic mushrooms. This collaboration aims to develop an effective treatment model if approved by the FDA, highlighting Compass Pathways' commitment to innovative mental health solutions.

Verona Pharma Plc

Verona Pharma Plc's Financial Successes Propel Growth Amid Lackluster Revenue in Q4 2023

Verona Pharma Plc, a prominent player in the pharmaceutical industry, has recently made strategic moves to strengthen its financial position, enabling continued growth. Despite a minor increase in borrowings, the company has successfully enhanced its Leverage Ratio, surpassing its own average and outperforming 16 competitors within the industry. These developments have significant implications for the company's overall trajectory.
Verona Pharma Plc has managed to boost its Leverage Ratio to 0.11 in the third quarter of 2023. This ratio exceeds the company's typical average and ranks higher than its Leverage Ratio in the previous quarter. What makes this achievement even more noteworthy is that 16 other companies in the industry reported lower Leverage Ratios during the same period, highlighting Verona Pharma's superior financial standing.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com